Safety assessment regarding use of glucosamine sulfate by patients whose dietary potassium intake is restricted

Yasuko Asahina, Satoko Hori, Yasufumi Sawada

Research output: Contribution to journalArticle

Abstract

Hyperkalemia is common in patients with renal disease, and is sometimes caused by dietary potassium intake. We aimed to determine and compare the content of potassium in nine brands of glucosamine supplements sold in the Japanese market and via the Internet. The potassium content was 0.165-3 mg per daily dose in Japanese products, which contained glucosamine hydrochloride or N-acetylglucosamine, while the content in foreign products, in which glucosamine was sulfated, was 197-280 mg. Our results show that the potassium content in glucosamine sulfate supplements can correspond to 20% of the maximum daily intake of potassium by patients on hemodialysis, because the products sometimes contain glucosamine as glucosamine sulfate potassium chloride for stabilization. Although it is not permitted to sell glucosamine sulfate as food in Japan, consumers can easily buy foreign products that contain glucosamine sulfate via the Internet, and those products rarely indicate the potassium content. Health professionals should pay attention to patients' use of glucosamine supplements, especially when patients' dietary potassium intake needs to be restricted.

Original languageEnglish
Pages (from-to)271-275
Number of pages5
JournalYakugaku Zasshi
Volume130
Issue number2
DOIs
Publication statusPublished - 2010 Feb 1
Externally publishedYes

Fingerprint

Dietary Potassium
Glucosamine
Safety
Potassium
Internet
Hyperkalemia
Potassium Chloride
Acetylglucosamine
Renal Dialysis
Japan

Keywords

  • Dietary supplement
  • Glucosamine
  • Hyperkalemia
  • Potassium

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Safety assessment regarding use of glucosamine sulfate by patients whose dietary potassium intake is restricted. / Asahina, Yasuko; Hori, Satoko; Sawada, Yasufumi.

In: Yakugaku Zasshi, Vol. 130, No. 2, 01.02.2010, p. 271-275.

Research output: Contribution to journalArticle

Asahina, Yasuko ; Hori, Satoko ; Sawada, Yasufumi. / Safety assessment regarding use of glucosamine sulfate by patients whose dietary potassium intake is restricted. In: Yakugaku Zasshi. 2010 ; Vol. 130, No. 2. pp. 271-275.
@article{92194da5f90042629562f7e17d15fffd,
title = "Safety assessment regarding use of glucosamine sulfate by patients whose dietary potassium intake is restricted",
abstract = "Hyperkalemia is common in patients with renal disease, and is sometimes caused by dietary potassium intake. We aimed to determine and compare the content of potassium in nine brands of glucosamine supplements sold in the Japanese market and via the Internet. The potassium content was 0.165-3 mg per daily dose in Japanese products, which contained glucosamine hydrochloride or N-acetylglucosamine, while the content in foreign products, in which glucosamine was sulfated, was 197-280 mg. Our results show that the potassium content in glucosamine sulfate supplements can correspond to 20{\%} of the maximum daily intake of potassium by patients on hemodialysis, because the products sometimes contain glucosamine as glucosamine sulfate potassium chloride for stabilization. Although it is not permitted to sell glucosamine sulfate as food in Japan, consumers can easily buy foreign products that contain glucosamine sulfate via the Internet, and those products rarely indicate the potassium content. Health professionals should pay attention to patients' use of glucosamine supplements, especially when patients' dietary potassium intake needs to be restricted.",
keywords = "Dietary supplement, Glucosamine, Hyperkalemia, Potassium",
author = "Yasuko Asahina and Satoko Hori and Yasufumi Sawada",
year = "2010",
month = "2",
day = "1",
doi = "10.1248/yakushi.130.271",
language = "English",
volume = "130",
pages = "271--275",
journal = "Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan",
issn = "0031-6903",
publisher = "Pharmaceutical Society of Japan",
number = "2",

}

TY - JOUR

T1 - Safety assessment regarding use of glucosamine sulfate by patients whose dietary potassium intake is restricted

AU - Asahina, Yasuko

AU - Hori, Satoko

AU - Sawada, Yasufumi

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Hyperkalemia is common in patients with renal disease, and is sometimes caused by dietary potassium intake. We aimed to determine and compare the content of potassium in nine brands of glucosamine supplements sold in the Japanese market and via the Internet. The potassium content was 0.165-3 mg per daily dose in Japanese products, which contained glucosamine hydrochloride or N-acetylglucosamine, while the content in foreign products, in which glucosamine was sulfated, was 197-280 mg. Our results show that the potassium content in glucosamine sulfate supplements can correspond to 20% of the maximum daily intake of potassium by patients on hemodialysis, because the products sometimes contain glucosamine as glucosamine sulfate potassium chloride for stabilization. Although it is not permitted to sell glucosamine sulfate as food in Japan, consumers can easily buy foreign products that contain glucosamine sulfate via the Internet, and those products rarely indicate the potassium content. Health professionals should pay attention to patients' use of glucosamine supplements, especially when patients' dietary potassium intake needs to be restricted.

AB - Hyperkalemia is common in patients with renal disease, and is sometimes caused by dietary potassium intake. We aimed to determine and compare the content of potassium in nine brands of glucosamine supplements sold in the Japanese market and via the Internet. The potassium content was 0.165-3 mg per daily dose in Japanese products, which contained glucosamine hydrochloride or N-acetylglucosamine, while the content in foreign products, in which glucosamine was sulfated, was 197-280 mg. Our results show that the potassium content in glucosamine sulfate supplements can correspond to 20% of the maximum daily intake of potassium by patients on hemodialysis, because the products sometimes contain glucosamine as glucosamine sulfate potassium chloride for stabilization. Although it is not permitted to sell glucosamine sulfate as food in Japan, consumers can easily buy foreign products that contain glucosamine sulfate via the Internet, and those products rarely indicate the potassium content. Health professionals should pay attention to patients' use of glucosamine supplements, especially when patients' dietary potassium intake needs to be restricted.

KW - Dietary supplement

KW - Glucosamine

KW - Hyperkalemia

KW - Potassium

UR - http://www.scopus.com/inward/record.url?scp=76349092493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76349092493&partnerID=8YFLogxK

U2 - 10.1248/yakushi.130.271

DO - 10.1248/yakushi.130.271

M3 - Article

VL - 130

SP - 271

EP - 275

JO - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

JF - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

SN - 0031-6903

IS - 2

ER -